# Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

> **NCT00352300** · PHASE1 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 43 (actual)

## Conditions studied

- Fallopian Tube Carcinoma
- Infectious Disorder
- Neutropenia
- Ovarian Carcinosarcoma
- Primary Peritoneal Carcinoma
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer

## Interventions

- **PROCEDURE:** Adjuvant Therapy
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00352300
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2014-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352300, "Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00352300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*